Medicine and Dentistry
Breast Cancer
90%
Neoplasm
67%
Metastatic Breast Cancer
66%
Malignant Neoplasm
63%
microRNA
60%
Cohort Analysis
60%
Severe Acute Respiratory Syndrome Coronavirus 2
48%
Disease
44%
Overall Survival
43%
Infection
40%
Fluorodeoxyglucose F 18
40%
Circulating Tumor DNA
40%
Clinical Trial
40%
Circulating microRNA
32%
COVID-19
32%
Estrogen Receptor
32%
Metastatic Carcinoma
30%
Treatment Response
27%
Progression Free Survival
27%
Comorbidity
26%
Monotherapy
25%
Targeted Therapy
25%
Cancer Therapy
22%
Biological Marker
22%
Breast Cancer Screening
22%
Case-Control Study
20%
Neoadjuvant Therapy
20%
Gamma Urogastrone
20%
Epidermal Growth Factor Receptor 2
20%
Capecitabine
20%
Retrospective Cohort Study
20%
Female Genital Tract Cancer
20%
Locally Advanced Breast Cancer
20%
Mammography
20%
Computer Assisted Tomography
20%
Ex Vivo
20%
Cancer Growth
20%
Sulfhemoglobinemia
20%
Peripheral Lymphocyte
20%
Disease Free Survival
20%
Positron Emission Tomography-Computed Tomography
20%
Transfer Cell
20%
Cost-Effectiveness Analysis
20%
Triple Negative Breast Cancer
20%
Estrogen Receptor Positive Breast Cancer
20%
Postmenopause
20%
Cancer Surgery
20%
CDK4/6 Inhibitor
20%
Polyethylene Terephthalate
20%
Experimental Therapy
20%
Pharmacology, Toxicology and Pharmaceutical Science
Metastatic Breast Cancer
100%
Cohort Study
64%
SARS Coronavirus
60%
Malignant Neoplasm
48%
Estrogen Receptor
45%
Infection
40%
Polyethylene Terephthalate
40%
Overall Survival
37%
Breast Cancer
37%
Neoplasm
35%
Disease
30%
Comorbidity
30%
Clinical Trial
24%
Progression Free Survival
21%
Gamma Urogastrone
20%
Epidermal Growth Factor Receptor 2
20%
Circulating Tumor DNA
20%
Ribociclib
20%
Hematologic Disease
20%
Endocrine Therapy
20%
Receptor
20%
Monotherapy
20%
Fluorodeoxyglucose F 18
20%
Survival Time
20%
Disease Free Survival
20%
Capecitabine
20%
microRNA
20%
Estrogen Receptor Positive Breast Cancer
20%
Frailty
20%
Anticancer Drug
20%
Retrospective Study
12%
Severe Acute Respiratory Syndrome
10%
Dyspnea
10%
Coughing
10%
Acute Disease
10%
Walking Difficulty
10%
Circulating microRNA
8%
Metastasis
8%
Biological Marker
8%
Neutropenia
7%
Myelodysplastic Syndrome
6%
Acute Leukemia
6%
Adverse Outcome
6%
microRNA 107
5%
Recurrent Disease
5%
Survival Rate
5%
Biochemistry, Genetics and Molecular Biology
Positron Emission Tomography-Computed Tomography
60%
MicroRNA
60%
Circulating Tumor DNA
40%
Estrogen Receptor
30%
Breast Cancer Screening
21%
Peripheral Blood Lymphocyte
20%
Case-Control Study
20%
Survival Time
20%
Phosphotransferase
20%
Kinase
20%
Postmenopause
20%
S100A7
20%
Tumor Progression
20%
Dynamics
20%
Genomics
20%
Cancer Cell
15%
Interleukin-1
13%
Lymphocyte
13%
Real-Time Polymerase Chain Reaction
10%
Oncogene
6%
Small Molecule
6%
Cancer Immunotherapy
6%
Calcium-Binding Protein
6%
Antineoplastic Activity
6%
Cancer Stem Cell
6%
Solution and Solubility
6%
Droplet Digital Polymerase Chain Reaction
5%
